Industry supports Australia’s new price deal
pharmafile | September 3, 2010 | News story | Sales and Marketing | Australia, global pricing, price cuts
Australia’s pharmaceutical industry is urging the country’s legislators to pass a new medicines pricing bill that aims to save Aus$1.9 billion (US$1.7 billion) over a five-year period.
Medicines Australia has written to a senate committee urging that the Parliament should pass the legislation before 1 October.
Medicines Australia chief executive Dr Brendan Shaw said the legislation would deliver significant benefit to taxpayers and consumers.
“This agreement gives pricing certainty to Australia’s medicines industry,” Dr Shaw said.
“Importantly, it will also save the taxpayer $1.86 billion and will mean cheaper scripts for patients.
“Hundreds of medicines commonly prescribed to treat high cholesterol, hypertension, asthma, cardiovascular disease, rheumatoid arthritis and depression will become cheaper for patients currently paying the non-concessional rate.”
Andrew McConaghie
Related Content

Australia pauses AstraZeneca vaccine for people under 60
Australia will now only recommend that people over 60 receive the AstraZeneca vaccine due to …

Australian study sees 70% HPV reduction in gay and bisexual men
A school-based human papillomavirus (HPV) vaccination study programme, led by Monash University and Alfred Health, …

Australian PM calls for domestic mRNA vaccine production
Australian Prime Minister, Scott Morrison, has invited proposals from pharmaceutical firms to establish domestic manufacturing …






